Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:ibs [03.13.2019]
sallieq [Further researxh]
home:diseases:ibs [03.15.2019] (current)
sallieq [Further research]
Line 53: Line 53:
  
 In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. ​  ​(({{pubmed>​long:​25947920}})) In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. ​  ​(({{pubmed>​long:​25947920}}))
 +
 +Mast cell activation syndromes ​  ​(({{pubmed>​long: ​   28780942}}))  ​
 +
 +Gastrointestinal (GI) symptoms are commonly reported in patients with mast cell disease. ​ (({{pubmed>​long: ​   30007461}}))  ​
 +
 + Mast cells are located in close proximity to the vasculature,​ and vasoactive mediators released upon their activation can promote endothelial activation leading to blood brain barrier (BBB) dysfunction. ​ (({{pubmed>​long: ​   30837844}}))  ​
 +
 +Mast cell activation plays an important role in stress-mediated disease pathogenesis. ​  ​(({{pubmed>​long:​30837843}}))  ​
 +
  
  
home/diseases/ibs.txt · Last modified: 03.15.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.